Regarding Nextellis: personally I don’t think we should have given Mithra 1 cent for the US distribution rights . The acceptance of the quality, price and all other reasons like side effects and ease of use is determined by the consumer and repeat business. From all reports I have observed since sales began in USA there is nothing there that gives me confidence in the long term success of achieving an acceptable market share. By this I mean bottom line profitability. It makes no sense whatsoever to buy market share should expenses outweigh profit. I hope and believe our new CEO will have very quickly seen this. I am sick and tired of their spruiking about other products being complimentary to this particular product. We as made clear 4 years ago paid more than twice as much ( Mithra agreement) as other Distributors for a far smaller market potential . I have always been suspicious of Why!
MYX Price at posting:
$3.06 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)